



November 5, 2013

Biocept Expands Board of Directors with Two Distinguished Appointments

Dr. Marsha A. Chandler and Bruce A. Huebner Bring Life Sciences Relationships

SAN DIEGO, November 5, 2013 — Biocept, Inc., today announced the appointment of Marsha A. Chandler, Ph.D. and Bruce A. Huebner as independent directors.

Dr. Chandler is currently the Executive Vice President and Chief Operating Officer of the Salk Institute for Biological Studies. She manages approximately 1000 scientific and administrative personnel and oversees all institutional fiscal, administrative and fund-raising activities. Reporting to her at the Salk Institute are the Vice Presidents for Scientific Services, Academic and Administrative Services, Development and Communication and the Chief Financial Officer as well as the Executive Directors of Core Research Facilities and the Office of Technology Development. She previously served as Senior Vice Chancellor for Academic Affairs at the University of California, San Diego, where she was the chief academic officer responsible for policy and decision making for all academic programs and faculty appointments and performance reviews. From 2003-2004, she served as Acting Chancellor of the University. Dr. Chandler is a Fellow of the Royal Society of Canada, the highest academic honor bestowed in that country. She received her Ph.D. from the University of North Carolina at Chapel Hill.

Mr. Huebner brings extensive executive management experience in multiple clinical diagnostic companies to Biocept's Board of Directors. In addition to his position as managing director at LynxCom Partners, Mr. Huebner is Chairman of the Board of Directors of Vermillion, Inc., a molecular diagnostics company that focuses on women's health in the area of gynecological cancers and other related diseases. Previously, he was President and Chief Executive Officer of TrovaGene, Inc., a developer of molecular diagnostics tests and President of Osmetech Molecular Diagnostics, where he led the company to securing FDA clearance for and commercialization of four molecular diagnostic microarray products. In addition, Mr. Huebner was President and Chief Operating Officer of Nanogen, Inc., a nanotechnology/microarray company, and Executive Vice President and Chief Officer of Gen-Probe Incorporated, which today is one of the world leaders in the development of nucleic acid tests for infectious diseases. Huebner has also served on the board of Corgenix Medical and AlliedPath, a private reference lab that focused on cancer diagnostics for solid tumors. He is currently on the board of the Pasadena BioScience Collaborative, a non-profit technology incubator company.

"We are very pleased that Dr. Chandler and Mr. Huebner have joined our board. They bring a wealth of experience and significant achievements in both the business and academic arenas. They are accomplished professionals with significant leadership experience and prominence within the scientific community," said Biocept Executive Chairman, David F. Hale. "We welcome them to Biocept's leadership team and look forward to the roles they will play in helping shape our strategic direction as the Company moves forward."

About Biocept, Inc.

Biocept, Inc., headquartered in San Diego, California, is a commercial stage oncology diagnostics company focused on providing information on patients' tumors to physicians using its proprietary technology platforms to help improve individual patient treatment. Biocept has developed proprietary technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians with important prognostic and predictive information to enhance individual treatment of their patients with cancer. Biocept currently offers its OncoCEE-BR™ test for breast cancer and plans to introduce tests for other solid tumors.

Contact:

The Ruth Group

Melanie Sollid

(646) 536-7023

